Poly Medicure's FY26 annual report shows a 13.4% income rise to Rs 1,995.3 crore. However, Profit After Tax (PAT) saw a 5.3% decline to Rs 320.7 crore. Strategic acquisitions in Italy and Netherlands are noted.
Poly Medicure FY26 Results
Income Rs 1,995.3 Cr; PAT Rs 320.7 Cr.
Reader Takeaway: Healthy revenue growth driven by acquisitions is offset by a recent dip in profitability.
What just happened
Poly Medicure Limited (POLYMED) reported its annual results for FY 2025-26. Total income grew by 13.4% year-on-year to Rs 1,995.3 crore. However, the Profit After Tax (PAT) for the fiscal year decreased by 5.3% to Rs 320.7 crore compared to Rs 338.6 crore in the previous year. EBITDA saw a marginal dip of 0.2% to Rs 457.7 crore.
Why this matters
The company's top-line growth indicates successful expansion, likely fueled by its recent strategic acquisitions. However, the decline in PAT and the flat EBITDA suggest potential pressure on margins or increased operational costs associated with integration and expansion.
The backstory
Poly Medicure is a leading manufacturer of medical devices. In FY 2025-26, the company focused on strengthening its presence in key verticals by acquiring Citieffe in Italy and PendraCare in the Netherlands. It operates 15 manufacturing plants across 5 countries, with a significant annual production capacity and a large patent portfolio.
What changes now
Investors will be looking for signs of how the newly acquired entities are contributing to profitability and how effectively their integration is progressing. The company's strategic focus remains on expanding its global footprint and enhancing its product portfolio.
Risks to watch
Key risks identified include global economic volatility, supply chain disruptions, foreign exchange fluctuations, and intensifying competition in the medical devices sector. Management is focused on mitigating these through global expansion and R&D.
Peer comparison
(No verified peer comparison data available from the filing for this period.)
Context metrics (time-bound)
- Total Income: Rs 1,995.3 crore (FY 2025-26) vs Rs 1,758.9 crore (FY 2024-25)
- Revenue from Operations: Rs 1,875.2 crore (FY 2025-26) vs Rs 1,669.8 crore (FY 2024-25)
- EBITDA: Rs 457.7 crore (FY 2025-26) vs Rs 458.6 crore (FY 2024-25)
- Profit After Tax (PAT): Rs 320.7 crore (FY 2025-26) vs Rs 338.6 crore (FY 2024-25)
What to track next
Investors should monitor the integration progress of Citieffe and PendraCare and their impact on the company's profit margins. Future quarterly results will provide more clarity on the sustainability of revenue growth and profitability improvements.